Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$3.12 USD
0.00 (0.00%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $3.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.12 USD
0.00 (0.00%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $3.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Zacks News
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
by Zacks Equity Research
Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Trevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Trevi Therapeutics, Inc. (TRVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season?
by Zacks Equity Research
Trevi Therapeutics (TRVI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.
Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.
Merck (MRK) Q1 Earnings & Sales Beat, COVID Drug Adds $3.3B
by Zacks Equity Research
Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
by Zacks Equity Research
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
by Zacks Equity Research
The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.
KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study
by Zacks Equity Research
KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
by Zacks Equity Research
TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.
Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice
by Zacks Equity Research
Does Trevi Therapeutics, Inc. (TRVI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Moderna (MRNA) Initiates Early-Stage Flu Vaccine Study
by Zacks Equity Research
Moderna's (MRNA) two vaccine candidates, mRNA-1020 and mRNA-1030, target both hemagglutinin and neuraminidase protein for providing better protection against the influenza virus. The company initiates a phase I/II study.
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
by Zacks Equity Research
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.
Rhythm Pharmaceuticals (RYTM) Down Due to Study Design Changes
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.
Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate
by Zacks Equity Research
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same. Stock rises.
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
by Zacks Equity Research
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
Here's Why Trevi Therapeutics, Inc. (TRVI) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
5 Stocks With Rising P/E Are Good Buys
by Sanghamitra Saha
Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.
Here's Why Trevi Therapeutics, Inc. (TRVI) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Trevi Therapeutics, Inc. (TRVI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Trevi Therapeutics' (TRVI) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Trevi Therapeutics (TRVI).